Back to Pennsylvania

HR565 • 2025

A Resolution designating the month of September 2026 as "Prostate Cancer Awareness Month" in Pennsylvania.

A Resolution designating the month of September 2026 as "Prostate Cancer Awareness Month" in Pennsylvania.

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
McNEILL
Last action
2026-06-12
Official status
Referred to HEALTH, June 12, 2026
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

A Resolution designating the month of September 2026 as "Prostate Cancer Awareness Month" in Pennsylvania.

A Resolution designating the month of September 2026 as "Prostate Cancer Awareness Month" in Pennsylvania.

What This Bill Does

  • A Resolution designating the month of September 2026 as "Prostate Cancer Awareness Month" in Pennsylvania.

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2026-06-12 HEALTH

    Referred to HEALTH, June 12, 2026

Official Summary Text

A Resolution designating the month of September 2026 as "Prostate Cancer Awareness Month" in Pennsylvania.

Current Bill Text

Read the full stored bill text
PRINTER'S NO. 3596
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE RESOLUTION
No. 565
Session of
2026
INTRODUCED BY McNEILL, VENKAT, GREINER, DOUGHERTY, COOK,
DIAMOND, HOHENSTEIN, McANDREW, GUZMAN, GUENST, NEILSON,
RIVERA, COOPER, CONKLIN, PASHINSKI, SANCHEZ, DEASY AND
CIRESI, JUNE 10, 2026
REFERRED TO COMMITTEE ON HEALTH, JUNE 12, 2026
A RESOLUTION
Designating the month of September 2026 as "Prostate Cancer
Awareness Month" in Pennsylvania.
WHEREAS, The prostate is a small gland found only in men and
located below the bladder; and
WHEREAS, In some cases, prostate cancer can make the prostate
enlarged; and
WHEREAS, Prostate Cancer Research, a nonprofit organization
under the National Cancer Research Institute, reports that the
risk of prostate cancer increases with age with most cases
diagnosed in men over 50 years of age; and
WHEREAS, According to the Prostate Conditions Education
Council, 1 in 8 American men will get prostate cancer and 1 in
41 men will die from prostate cancer; and
WHEREAS, The American Cancer Society estimated that more than
13,000 new cases of prostate cancer will have been diagnosed in
2025 in Pennsylvania; and
WHEREAS, The American Cancer Society estimated that 1,500
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
Pennsylvanians will have died of prostate cancer in 2025; and
WHEREAS, The Centers for Disease Control and Prevention
describes symptoms of prostate cancer that include difficulty
starting urination, weak or interrupted flow of urine, trouble
emptying the bladder completely, pain or burning during
urination, blood in the urine and pain in the back, hips or
pelvis; and
WHEREAS, Prostate cancer can be dormant in a person's body
for up to 20 years without symptoms, increasing the chance that
a person may be sick without the person's knowledge; and
WHEREAS, The American Cancer Society recommends that men with
an average risk of prostate cancer start screening for prostate
cancer at 50 years of age; and
WHEREAS, For men at a high risk of developing prostate cancer
and men who have a first-degree relative diagnosed with prostate
cancer at an early age, screening should begin at 45 years of
age; and
WHEREAS, For men at even greater risk, including those with
more than one first-degree relative who had prostate cancer at
an early age, screening should begin at 40 years of age; and
WHEREAS, Men should consult with their physician about the
benefits of screening for prostate cancer; and
WHEREAS, There are two tests used by physicians to screen for
prostate cancer: a prostate-specific antigen test, which
measures the level of prostate-specific antigen in the blood,
and a digital rectal examination, which detects abnormalities of
the prostate; and
WHEREAS, If abnormalities are noted from either screening, a
biopsy may be recommended to assist in diagnosing potential
prostate cancer; therefore be it
20260HR0565PN3596 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
RESOLVED, That the House of Representatives designate the
month of September 2026 as "Prostate Cancer Awareness Month" in
Pennsylvania.
20260HR0565PN3596 - 3 -
1
2
3